T-Cells Attacking Cancer Cell

Pioneering The First Cell Therapy For Solid Tumors

Back in February, the FDA approved the first cell therapy for solid tumors — Iovance Biotherapeutics’ Amtagvi (lifileucel). Amtagvi is an autologous T-cell therapy — or more specifically, a tumor-infiltrating lymphocyte (TIL) therapy (the first TIL therapy to be approved by the FDA) — for patients with previously treated, unresectable or metastatic melanoma. Learn what sets TILs apart from its other T-cell therapy counterparts and about Iovance’s preparation leading up to this monumental approval.

KLSC_launch (1)

Industry Leaders Launch Keystone LifeSci Collaborative, a New Partnership to Support Southeastern Pennsylvania’s Life Science Sector

Life science leaders and community partners across Southeastern Pennsylvania launched a business-centered collaborative forum today called the Keystone LifeSci Collaborative. This partnership will serve as a forum for life sciences industry leaders from across the region to collaborate in growing the industry and strengthening the talent pipeline into life sciences careers.